DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
stomatitis
5-FU
mucositis
5-FU
neurotoxicity
5-FU
diarrhea
5-FU
myelosuppression
5-FU